MedTrace Logo

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

NCT05575167 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2025-04-27

No results posted yet for this study

Summary

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Zoledronate or Alendronate

infusion (for zoledronate) or oral digestion (for alendronate)

Sponsors & Collaborators

  • 424 General Military Hospital

    lead OTHER

Principal Investigators

  • Willem Lems, Prof · ECTS Clinical Action Group

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • France
  • Greece
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05575167 on ClinicalTrials.gov